Margarita Majem - Publications

Correction: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 15, 2026

Soluble Immune Checkpoints as Prognostic Biomarkers in Small Cell Lung Cancer Patients Treated with Chemotherapy and Anti-PD-L1.

Journal: International journal of molecular sciences

Published: June 12, 2026

Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 21, 2026

Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy.

Journal: Cancer immunology, immunotherapy : CII

Published: February 02, 2026

Timing of definitive pleural intervention within systemic anticancer therapy in malignant pleural effusion from high-response lung cancers: a retrospective single-center cohort study.

Journal: Translational lung cancer research

Published: December 20, 2025

A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer.

Journal: Future oncology (London, England)

Published: December 12, 2025

Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial.

Journal: The Lancet. Oncology

Published: October 01, 2025

Sotorasib in Advanced KRAS G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS Metastases.

Journal: JTO clinical and research reports

Published: September 07, 2025

Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.

Journal: Targeted oncology

Published: September 02, 2025

Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 01, 2025

Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 29, 2025

Small cell lung cancer: a therapeutic update in the era of immunotherapy and beyond-a narrative review.

Journal: Chinese clinical oncology

Published: August 25, 2025